Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety of Branebrutinib in Healthy Participants
NCT05303220Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of branebrutinib in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren's syndrome and 1 more (9 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 5 more. Started Apr 2022; status: completed.
02
Drugs
branebrutinib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)Sjogren's syndromeatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05303220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303220.